Vertex PharmaceuticalsWBO:VRTX +1.43%85 PS Ratio is 11.28 as of Jul. 04, 2026, which is 0% below its 10-year median of 11.30. GuruFocus rates WBO:VRTX with a GF Score™ of 85/100 and a GF Value™ of €439.23 (Fairly Valued). The stock has 6 warning signs investors should review. Among 933 Biotechnology companies, Vertex Pharmaceuticals ranks worse than 53.05% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vertex Pharmaceuticals's share price is €460.55.
Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €40.82. Hence, Vertex Pharmaceuticals's PS Ratio for today is 11.28.
Warning Sign:
Vertex Pharmaceuticals Inc stock PS Ratio (=11.12) is close to 1-year high of 11.12.
The historical rank and industry rank for Vertex Pharmaceuticals's PS Ratio or its related term are showing as below:
WBO:VRTX'
s PS Ratio Range Over the Past 10 Years
Min: 6.55 Med: 11.3 Max: 18.98
Current: 11.12
During the past 13 years, Vertex Pharmaceuticals's highest PS Ratio was 18.98. The lowest was 6.55. And the median was 11.30.
WBO:VRTX's PS Ratio is ranked worse than 53.05% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs WBO:VRTX: 11.12
During the past 12 months, the average Revenue per Share Growth Rate of Vertex Pharmaceuticals was 10.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 10.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 14.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 26.70% per year.
During the past 13 years, Vertex Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 129.40% per year. The lowest was -32.50% per year. And the median was 17.20% per year.
Back to Basics: PS Ratio
Vertex Pharmaceuticals (WBO:VRTX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vertex Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Vertex Pharmaceuticals's Share Price of today is €460.55. Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €40.82.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Vertex Pharmaceuticals (WBO:VRTX) has a PS Ratio of 11.28 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vertex Pharmaceuticals and its competitors. This is near median its historical median of 11.30. Over the past decade, Vertex Pharmaceuticals' PS Ratio has ranged from 6.55 to 18.98. According to the industry distribution chart, Vertex Pharmaceuticals ranks #495 out of 933 companies in the Biotechnology industry, placing it in the top 53.1%.
Is Vertex Pharmaceuticals' PS Ratio too high?
Vertex Pharmaceuticals' current PS Ratio of 11.28 is near median its 10-year median of 11.30. Over the past 10 years, this metric has ranged from a low of 6.55 to a high of 18.98. The Biotechnology industry median PS Ratio is 9.64. Vertex Pharmaceuticals' value of 11.28 is 17% above this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #495 out of 933 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vertex Pharmaceuticals has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' PS Ratio compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #495 out of 933 companies for PS Ratio. This places Vertex Pharmaceuticals in the lower half of its industry. The industry median PS Ratio is 9.64. Vertex Pharmaceuticals' value of 11.28 is 17% above this benchmark. Historically, Vertex Pharmaceuticals' own PS Ratio has ranged from 6.55 to 18.98 over the past decade. While the company's 10-year median is 11.30 vs. the industry median of 9.64, Vertex Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current PS Ratio of 11.28 is 17% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vertex Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current PS Ratio is 11.28, which is near median its own 10-year median of 11.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €439.23, compared to a current price of €460.55 — trading 4.9% above its estimated fair value. The current PS Ratio is 11.28, which is near median its 10-year median of 11.30 and 17% above the Biotechnology industry median of 9.64. Vertex Pharmaceuticals' overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current PS Ratio is 11.28 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be overvalued.
The current stock price of €460.55 is trading 4.9% above its estimated GF Value™ of €439.23.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for WBO:VRTX:
PS Ratio: 11.28 (near median its 10-year median of 11.30)
GF Value™: €439.23 vs. price of €460.55 (4.9% above fair value)
Industry Position: 17% above the Biotechnology median (#495 of 933)
No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
85GF Score
Get the complete analysis for WBO:VRTX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VRTX has been successfully added to your 
